Halidou Tinto

Halidou Tinto is a professor of parasitology and global health scientist with research that has contributed to understanding and combating malaria in Sub-Saharan Africa. Tinto founded the Clinical Research Unit of Nanaro (CRUN) in Burkina Faso as part of the Institut de Recherche en Sciences de la Santé (IRSS). Tinto attended the University of Mali to study pharmacy, before obtaining a master's degree in microbiology and biochemistry from the University of Ouagadougou in Burkina Faso. Much of his later research was inspired from his work in Tinga Robert Guiguemdé's lab at Centre Muraz.

R21 vaccine achievements Following 2014 up until 2022, through the IRSS in Burkina Faso, Halidou Tinto worked with Oxford University on the development of an improved RTS,S malaria vaccine, called R21/Matrix-M. Tinto's research, funded by the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2), Wellcome Trust, and NIHR Oxford Biomedical Research Centre, conducted a clinical trial that found the new R21 vaccine to have an improved efficacy of 77% when given with a higher adjuvant dose in the 12 months following the initial 3 dose regimen. This was an achievement in Tinto's career as he was the Principal Investigator in these phase 2 trials, which led to the R21 being the only malaria vaccine to meet WHO's 75% efficacy standard.

Appointments and awards

Appointments

2014 - 2015: Scientific Director of Centre Muraz as below. The name in Science 2021 - Academic Union, Oxford Honorary Professor 2022 - Academic Union, Oxford European Quality Award 2022 - Europe Business Academy